Accepted Manuscript

Design and synthesis of novel xanthine derivatives as potent and selective A_{2B} adenosine receptor antagonists for the treatment of chronic inflammatory airway diseases

Sujay Basu, Dinesh A. Barawkar, Vidya Ramdas, Meena Patel, Yogesh Waman, Anil Panmand, Santosh Kumar, Sachin Thorat, Minakshi Naykodi, Arnab Goswami, B. Srinivasa Reddy, Vandna Prasad, Sandhya Chaturvedi, Azfar Quraishi, Suraj Menon, Shalini Paliwal, Abhay Kulkarni, Vikas Karande, Indraneel Ghosh, Syed Mustafa, Siddhartha De, Vaibhav Jain, Ena Ray Banerjee, Sreekanth R. Rouduri, Venkata P. Palle, Anita Chugh, Kasim A. Mookhtiar

PII: S0223-5234(17)30268-4

DOI: 10.1016/j.ejmech.2017.04.014

Reference: EJMECH 9361

To appear in: European Journal of Medicinal Chemistry

Received Date: 15 November 2016

Revised Date: 1 April 2017 Accepted Date: 7 April 2017

Please cite this article as: S. Basu, D.A. Barawkar, V. Ramdas, M. Patel, Y. Waman, A. Panmand, S. Kumar, S. Thorat, M. Naykodi, A. Goswami, B.S. Reddy, V. Prasad, S. Chaturvedi, A. Quraishi, S. Menon, S. Paliwal, A. Kulkarni, V. Karande, I. Ghosh, S. Mustafa, S. De, V. Jain, E.R. Banerjee, S.R. Rouduri, V.P. Palle, A. Chugh, K.A. Mookhtiar, Design and synthesis of novel xanthine derivatives as potent and selective A_{2B} adenosine receptor antagonists for the treatment of chronic inflammatory airway diseases, *European Journal of Medicinal Chemistry* (2017), doi: 10.1016/j.eimech.2017.04.014.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



ACCEPTED MANUSCRIPT

Graphical abstract

 $\begin{array}{l} hA_{2B} \text{ binding } \textit{K}_i = 3.6 \text{ nM} \\ hA_{2B} \text{ functional } \textit{K}_i = 8.8 \text{ nM} \\ \% F = 42 \end{array}$

hA2B binding $K_i = 13.0 \text{ nM}$ hA2B functional $K_i = 8.0 \text{ nM}$ No CYP and hERG liability, not cytotoxic, %F = 76 Showed efficacy in Ovalbumin treated mice

Download English Version:

https://daneshyari.com/en/article/5158978

Download Persian Version:

https://daneshyari.com/article/5158978

<u>Daneshyari.com</u>